18F-FDG PET/CT successfully detected a recurrent mass and an inguinal lymph node in a patient with paratesticular rhabdomyosarcoma, which were missed by 99mTc-FAPI SPECT/CT.
Case Report (n=1)
Does 18F-FDG PET/CT improve detection of recurrence compared to 99mTc-FAPI SPECT/CT in alveolar paratesticular rhabdomyosarcoma?
18F-FDG PET/CT demonstrated superior efficacy compared to 99mTc-FAPI SPECT/CT in restaging alveolar paratesticular rhabdomyosarcoma.
We present a 19-year-old man with alveolar paratesticular rhabdomyosarcoma (RMS) who underwent restaging with both 18 F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)/ computed tomography (CT) and 99m Tc-fibroblast activation protein inhibitor (FAPI)-46 single-photon emission computed tomography (SPECT)/CT after the initial surgery. Despite normal retroperitoneal lymph nodes on CT, 18 F-FDG PET/CT revealed a recurrent mass in the spermatic cord stump and an inguinal lymph node, which was not detected by 99m Tc-FAPI SPECT/CT. Our case highlights the superior efficacy of 18 F-FDG PET/CT compared with 99m Tc-FAPI SPECT/CT in restaging paratesticular RMS, consistent with previous studies demonstrating the utility of 18 F-FDG PET/CT in the initial staging of RMS. This report underscores the importance of selecting the optimal imaging modality for accurate disease assessment and management in this aggressive and rare tumor subtype.
Tanha et al. (Thu,) conducted a case report in Alveolar paratesticular rhabdomyosarcoma (n=1). 18F-FDG PET/CT vs. 99mTc-FAPI-46 SPECT/CT was evaluated on Detection of recurrent mass and lymph node metastasis. 18F-FDG PET/CT successfully detected a recurrent mass and an inguinal lymph node in a patient with paratesticular rhabdomyosarcoma, which were missed by 99mTc-FAPI SPECT/CT.